Drugs for Atrial Flutter with Doses
Rate Control Medications
For acute rate control in hemodynamically stable atrial flutter, beta-blockers, diltiazem, or verapamil are the first-line agents, though achieving adequate rate control is more challenging than in atrial fibrillation due to less concealed AV nodal conduction. 1, 2
Beta-Blockers (Preferred in Most Patients)
- Metoprolol tartrate: 2.5-5 mg IV bolus over 2 minutes; up to 3 doses. Oral maintenance: 25-100 mg twice daily 3, 4
- Esmolol (preferred for acute situations due to rapid onset): 500 mcg/kg IV bolus over 1 minute, then 50-300 mcg/kg/min continuous infusion 3, 4, 2
- Metoprolol succinate (XL): 50-400 mg once daily (oral only) 3, 4
- Propranolol: 1 mg IV over 1 minute, up to 3 doses at 2-minute intervals. Oral: 10-40 mg three to four times daily 3, 4
- Atenolol: 25-100 mg once daily (oral only, renally eliminated) 3, 4
- Bisoprolol: 2.5-10 mg once daily (oral only) 3, 4
- Carvedilol: 3.125-25 mg twice daily (oral only) 3, 4
- Nadolol: 10-240 mg once daily (oral only) 3, 4
Nondihydropyridine Calcium Channel Blockers
- Diltiazem (preferred IV calcium channel blocker due to superior safety and efficacy): 0.25 mg/kg IV bolus over 2 minutes, may repeat 0.35 mg/kg over 2 minutes, then 5-15 mg/h continuous infusion. Oral maintenance: 120-360 mg once daily (extended release) 3, 4, 2
- Verapamil: 0.075-0.15 mg/kg (5-10 mg) IV bolus over 2 minutes, may give additional 10 mg after 30 minutes if no response, then 0.005 mg/kg/min (5 mg/h) infusion. Oral: 180-480 mg once daily (extended release) 3, 4
Critical caveat: Avoid nondihydropyridine calcium channel blockers in decompensated heart failure, advanced heart block, sinus node dysfunction without pacemaker, or pre-excitation syndromes 3, 1, 2
Digoxin
- Digoxin: 0.25 mg IV with repeat dosing to maximum of 1.5 mg over 24 hours. Oral maintenance: 0.125-0.25 mg once daily 3, 4
- Digoxin is generally less effective as monotherapy for rate control in active patients and should not be used alone 5
- Renally eliminated; increased mortality at plasma concentrations exceeding 1.2 ng/mL 4
Amiodarone (Second-Line for Rate Control)
- Amiodarone: 150-300 mg IV over 1 hour, then 10-50 mg/h over 24 hours. Oral maintenance: 100-200 mg once daily (loading dose 6-10 g over 2-4 weeks) 3, 4
- May be useful for rate control when other measures are unsuccessful or contraindicated, particularly in systolic heart failure when beta-blockers are contraindicated 3, 2
Important consideration: Higher doses of rate-control medications, and often combination therapy, are typically needed in atrial flutter compared to atrial fibrillation because the slower atrial rate paradoxically results in more rapid AV nodal conduction 1, 2
Rhythm Control Medications (Acute Cardioversion)
Ibutilide and dofetilide are the first-line pharmacological agents for acute cardioversion of atrial flutter, with class III drugs being more effective than class I agents for flutter conversion. 6, 7
Class III Antiarrhythmic Drugs (First-Line)
Ibutilide (IV only): Requires continuous electrocardiographic monitoring for at least 4 hours after infusion or until QTc returns to baseline to minimize risk of torsades de pointes 4, 6
- Correct hypokalemia and hypomagnesemia before administration 4
Dofetilide (oral): Requires hospitalization for initiation with continuous ECG monitoring 4, 6
- Baseline and follow-up testing includes 12-lead ECG, serum creatinine for creatinine clearance estimation, serum potassium and magnesium every 3-6 months 4
Class IC Antiarrhythmic Drugs (For Patients Without Structural Heart Disease)
Flecainide: Starting dose 50 mg every 12 hours for paroxysmal atrial flutter. May increase in 50 mg twice daily increments every 4 days. Maximum 300 mg/day for supraventricular arrhythmias 6, 8
Propafenone: Starting dose 150 mg every 8 hours or 225 mg every 12 hours (extended release). Usual dose 450-900 mg/day in divided doses 9
Major pitfall: Class IC drugs (flecainide, propafenone) can paradoxically increase ventricular rate in atrial flutter by organizing flutter to a slower atrial rate that conducts 1:1 through the AV node. Always combine with beta-blockers or calcium channel blockers 1, 6, 9, 8
Long-Term Rhythm Control (Maintenance Therapy)
For patients without structural heart disease, first-choice antiarrhythmic drugs include dronedarone, flecainide, propafenone, or sotalol 5
- Sotalol: Requires hospitalization for initiation with continuous ECG monitoring. Follow-up includes 12-lead ECG, serum creatinine, potassium and magnesium every 3-6 months 4
- Dronedarone: Baseline and follow-up AST/ALT within first 6 months, 12-lead ECG 4
- Amiodarone: Only drug recommended for patients with left ventricular ejection fraction <35% 5
Special Considerations
Pre-Excitation Syndromes (Wolff-Parkinson-White)
Avoid digoxin, nondihydropyridine calcium channel blockers, beta-blockers, and amiodarone in pre-excited atrial flutter, as these can accelerate conduction through the accessory pathway and precipitate ventricular fibrillation. 3, 1, 10
- Procainamide is the drug of choice for atrial flutter with pre-excitation 10
- Requires ECG monitoring during infusion for QRS widening, QTc prolongation, and blood pressure monitoring for hypotension 4, 10
Hemodynamic Instability
Immediate synchronized cardioversion is indicated for hemodynamically unstable patients (hypotension, acute heart failure, ongoing chest pain, altered mental status) who don't respond to pharmacological therapies. 3, 1, 2
Anticoagulation Requirements
Anticoagulation protocols for atrial flutter must follow the same guidelines as atrial fibrillation, with therapeutic anticoagulation for at least 3 weeks before and 4 weeks after cardioversion for flutter ≥48 hours or unknown duration. 3, 1, 6, 2
- Stroke risk in atrial flutter is approximately 3% annually 2
- For flutter <48 hours with high stroke risk, IV heparin, LMWH, or direct oral anticoagulants should be initiated before or immediately after cardioversion 3
Definitive Treatment Consideration
Catheter ablation of the cavotricuspid isthmus should be strongly considered as first-line therapy for symptomatic atrial flutter or flutter refractory to pharmacological rate control, with success rates exceeding 90% and low complication rates. 1, 6, 2